TLR4 agonist immunotherapy platform against cancer
Total raised: $11.2M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.05.2024 | Seed | $11.2M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.05.2024 | HEPHAISTOS-Pharma: Pioneering the Future of Cancer Treatment | HEPHAISTOS-Pharma, a groundbreaking biotechnology company based in France, has recently secured a substantial €4.5 million in seed funding to propel their innovative work in developing next-generation immunotherapies to combat cancer. At th... |
| 16.05.2024 | Hephaistos-Pharma Raises €10.3M in Funding | Hephaistos-Pharma, a Lyon, France-based biotechnology company developing immunotherapies against cancer, raised a total of $10.3M in Seed funding. The round included: a €4.5M led by Elaia with participation from xista sciences ventures, Fon... |
| 16.05.2024 | French biotech HEPHAISTOS-Pharma gets €4.5 million to develop next-gen of immunostimulants against cancer | - |
| 16.05.2024 | HEPHAISTOS-Pharma secures €4.5M Seed funding for cancer immunotherapies | HEPHAISTOS-Pharma, a biotechnology company developing next-generation immunotherapies against cancer that target innate immunity to increase patient cure rates, has completed its €4.5 million seed round to finance industrialisation and adva... |
| - | HEPHAISTOS-Pharma | “TLR4 agonist immunotherapy platform against cancer” |